Table of Contents

Introduction

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones

Appendix

Toll Like Receptor 4 - Pipeline Review, H1 2020

Summary

According to the recently published report 'Toll Like Receptor 4 – Pipeline Review, H1 2020'; Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 44 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes.

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

The report 'Toll Like Receptor 4 – Pipeline Review, H1 2020' outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 4, 15 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Oncology, Respiratory, Central Nervous System, Immunology, Cardiovascular, Genito Urinary System And Sex Hormones, Undisclosed, Ear Nose Throat Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Coronavirus Disease 2019 (COVID-19), Non Alcoholic Fatty Liver Disease (NAFLD), Inflammation, Solid Tumor, Acute Lung Injury, Acute Respiratory Distress Syndrome, Atherosclerosis, Chronic Liver Disease, Dengue Fever, Kidney Fibrosis, Liver Fibrosis, Pain, Sepsis, Acute Ischemic Stroke, Acute Liver Failure, Alzheimer's Disease, Autoimmune Disorders, Bacterial Sepsis, Breast Cancer, Bronchopulmonary Dysplasia, Chronic Asthma, Chronic Obstructive Pulmonary Disease (COPD), Crohn's Disease (Regional Enteritis), Cyst, Diffuse Large B-Cell Lymphoma, Drug Addiction, Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Hearing Disorders, Hepatic Injury, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Marginal Zone B-cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Necrotizing Enterocolitis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Pandemic Influenza, Peritonitis, Post-Operative Pain, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rheumatoid Arthritis, Schistosomiasis, Soft Tissue Sarcoma, Unspecified, Unspecified Rare Disease and Viral Respiratory Tract Infection.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope